European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 19 August 2026 - 14:23

Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 76, Status: Authorised

Submitted by Anonymous (not verified) on 19 August 2026 - 14:14

Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 76, Status: Authorised

EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 July 2026, 13:00 (CEST) to 2 July 2026, 16:00 (CEST)

Submitted by Anonymous (not verified) on 19 August 2026 - 13:42

EMA multi-stakeholder workshop on supporting innovation in cardiovascular medicines and medical devices in the EU, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 1 July 2026, 13:00 (CEST) to 2 July 2026, 16:00 (CEST)

Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 34, Status: Authorised

Submitted by Anonymous (not verified) on 19 August 2026 - 11:41

Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 34, Status: Authorised

Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Date of authorisation: 30/06/2025, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 19 August 2026 - 11:37

Human medicines European public assessment report (EPAR): Alyftrek, deutivacaftor / tezacaftor / vanzacaftor, Date of authorisation: 30/06/2025, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Date of authorisation: 27/05/2015, Revision: 26, Status: Authorised

Submitted by Anonymous (not verified) on 19 August 2026 - 11:33

Human medicines European public assessment report (EPAR): Jinarc, tolvaptan, Date of authorisation: 27/05/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzneuta, efbemalenograstim alfa, Date of authorisation: 21/03/2024, Revision: 6, Status: Authorised

Submitted by Anonymous (not verified) on 19 August 2026 - 10:55

Human medicines European public assessment report (EPAR): Ryzneuta, efbemalenograstim alfa, Date of authorisation: 21/03/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised

Submitted by Anonymous (not verified) on 19 August 2026 - 10:17

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 16, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness